NO20023485D0 - 1,3-disubstituerte pyrrolidiner som alfa-2- adrenoceptorantagonister - Google Patents

1,3-disubstituerte pyrrolidiner som alfa-2- adrenoceptorantagonister

Info

Publication number: NO20023485D0
Authority: NO; Norway
Prior art keywords: alpha; adrenoceptor antagonists; disubstituted pyrrolidines; pyrrolidines; disubstituted
Prior art date: 2000-01-28

Application number

NO20023485A

Other languages

English (en)

Other versions

NO20023485L (no

Inventor

Max Peter Seiler

Joachim Nozulak

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-28

Filing date

2002-07-22

Publication date

2002-07-22

2002-07-22 Application filed by Novartis Ag filed Critical Novartis Ag

2002-07-22 Publication of NO20023485D0 publication Critical patent/NO20023485D0/no

2002-09-03 Publication of NO20023485L publication Critical patent/NO20023485L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)

NO20023485A 2000-01-28 2002-07-22 1,3-disubstituerte pyrrolidiner som alfa-2- adrenoceptorantagonister NO20023485L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0002100.6A GB0002100D0 (en)	2000-01-28	2000-01-28	Organic compounds
PCT/EP2001/000861 WO2001055132A1 (en)	2000-01-28	2001-01-26	1,3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists

Publications (2)

Publication Number	Publication Date
NO20023485D0 true NO20023485D0 (no)	2002-07-22
NO20023485L NO20023485L (no)	2002-09-03

Family

ID=9884609

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20023485A NO20023485L (no)	2000-01-28	2002-07-22	1,3-disubstituerte pyrrolidiner som alfa-2- adrenoceptorantagonister

Country Status (28)

Country	Link
US (1)	US7012085B2 (no)
EP (1)	EP1257547B1 (no)
JP (1)	JP2003523353A (no)
KR (1)	KR20020069375A (no)
CN (2)	CN1178935C (no)
AR (1)	AR029463A1 (no)
AT (1)	ATE384715T1 (no)
AU (1)	AU768844B2 (no)
BR (1)	BR0107888A (no)
CA (1)	CA2398794C (no)
CO (1)	CO5261521A1 (no)
CZ (1)	CZ20022581A3 (no)
DE (1)	DE60132558T2 (no)
ES (1)	ES2296763T3 (no)
GB (1)	GB0002100D0 (no)
HU (1)	HUP0203836A3 (no)
IL (1)	IL150550A0 (no)
MX (1)	MXPA02007318A (no)
MY (1)	MY128639A (no)
NO (1)	NO20023485L (no)
NZ (1)	NZ520342A (no)
PE (1)	PE20011068A1 (no)
PL (1)	PL202473B1 (no)
PT (1)	PT1257547E (no)
RU (1)	RU2002121646A (no)
SK (1)	SK10802002A3 (no)
WO (1)	WO2001055132A1 (no)
ZA (1)	ZA200205991B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0002100D0 (en) *	2000-01-28	2000-03-22	Novartis Ag	Organic compounds
US6436972B1 (en)	2000-04-10	2002-08-20	Dalhousie University	Pyridones and their use as modulators of serine hydrolase enzymes
US20060058364A1 (en) *	2002-03-29	2006-03-16	Antti Haapalinna	Treatment of dependence and dependence related withdrawal symptoms
TWI417095B (zh)	2006-03-15	2013-12-01	Janssen Pharmaceuticals Inc	１，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
JP2008037850A (ja) *	2006-08-10	2008-02-21	Mitsubishi Tanabe Pharma Corp	新規置換ピペリジン誘導体
TW200845978A (en)	2007-03-07	2008-12-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en)	2007-03-07	2009-01-01	Janssen Pharmaceutica Nv	3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
BRPI0816767B8 (pt)	2007-09-14	2021-05-25	Addex Pharmaceuticals Sa	composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
US8273900B2 (en) *	2008-08-07	2012-09-25	Novartis Ag	Organic compounds
CN102143955B (zh)	2008-09-02	2013-08-14	Omj制药公司	作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物
CA2744138C (en)	2008-11-28	2015-08-11	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8946205B2 (en)	2009-05-12	2015-02-03	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
MY153913A (en)	2009-05-12	2015-04-15	Janssen Pharmaceuticals Inc	7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
RS53075B (en)	2009-05-12	2014-04-30	Janssen Pharmaceuticals Inc.	1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
US9012448B2 (en)	2010-11-08	2015-04-21	Janssen Pharmaceuticals, Inc.	1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
ES2552879T3 (es)	2010-11-08	2015-12-02	Janssen Pharmaceuticals, Inc.	Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
WO2012062750A1 (en)	2010-11-08	2012-05-18	Janssen Pharmaceuticals, Inc.	1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
GB2503187A (en) *	2011-09-15	2013-12-25	Univ Sussex	Composition for use in the treatment of neurodevelopmental disorders
US9073878B2 (en)	2012-11-21	2015-07-07	Zenith Epigenetics Corp.	Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Biaryl derivatives as bromodomain inhibitors
CN105073744B (zh) *	2012-12-21	2019-11-08	齐尼思表观遗传学有限公司	作为溴结构域抑制剂的新型杂环化合物
JO3368B1 (ar)	2013-06-04	2019-03-13	Janssen Pharmaceutica Nv	مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
BR112015031073B1 (pt)	2013-06-21	2022-11-29	Zenith Epigenetics Ltd	Compostos inibidores bicíclicos de bromodomínio e composição farmacêutica contendo os referidos compostos
CN105473581B (zh)	2013-06-21	2019-04-23	齐尼思表观遗传学有限公司	作为溴结构域抑制剂的新取代的双环化合物
WO2015015318A2 (en)	2013-07-31	2015-02-05	Zenith Epigenetics Corp.	Novel quinazolinones as bromodomain inhibitors
JO3367B1 (ar)	2013-09-06	2019-03-13	Janssen Pharmaceutica Nv	مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
LT3431106T (lt)	2014-01-21	2021-02-10	Janssen Pharmaceutica Nv	Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
KR20220039824A (ko)	2014-01-21	2022-03-29	얀센 파마슈티카 엔.브이.	대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
EP3227281A4 (en)	2014-12-01	2018-05-30	Zenith Epigenetics Ltd.	Substituted pyridinones as bromodomain inhibitors
CA2966303A1 (en)	2014-12-01	2016-06-09	Zenith Epigenetics Ltd.	Substituted pyridines as bromodomain inhibitors
EP3230277B1 (en)	2014-12-11	2019-09-18	Zenith Epigenetics Ltd.	Substituted heterocycles as bromodomain inhibitors
WO2016097863A1 (en)	2014-12-17	2016-06-23	Zenith Epigenetics Corp.	Inhibitors of bromodomains

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI95572C (fi)	1987-06-22	1996-02-26	Eisai Co Ltd	Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5185364A (en)	1988-01-15	1993-02-09	Abbott Laboratories	Aminomethyl-chroman and -thiochroman compounds
AU653837B2 (en) *	1991-04-17	1994-10-13	Pharmacia & Upjohn Company	Substituted phenylazacycloalkanes as CNS agents
GB9113031D0 (en)	1991-06-17	1991-08-07	Smithkline Beecham Plc	Compounds
FR2687146B1 (fr) *	1992-02-12	1994-04-01	Adir Cie	Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ATE243196T1 (de)	1994-03-09	2003-07-15	Novo Nordisk As	Piperidine und pyrrolidine
SE9802546D0 (sv) *	1998-07-15	1998-07-15	Ross Nicholas Waters	Medicinal product and method for treatment and prevention of dyskinesia
IT1303737B1 (it)	1998-11-11	2001-02-23	Smithkline Beecham Spa	Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1.
GB0002100D0 (en) *	2000-01-28	2000-03-22	Novartis Ag	Organic compounds

2000
- 2000-01-28 GB GBGB0002100.6A patent/GB0002100D0/en not_active Ceased
2001
- 2001-01-23 MY MYPI20010309A patent/MY128639A/en unknown
- 2001-01-25 AR ARP010100318A patent/AR029463A1/es unknown
- 2001-01-26 MX MXPA02007318A patent/MXPA02007318A/es active IP Right Grant
- 2001-01-26 US US10/182,090 patent/US7012085B2/en not_active Expired - Fee Related
- 2001-01-26 ES ES01946858T patent/ES2296763T3/es not_active Expired - Lifetime
- 2001-01-26 PE PE2001000086A patent/PE20011068A1/es not_active Application Discontinuation
- 2001-01-26 AT AT01946858T patent/ATE384715T1/de not_active IP Right Cessation
- 2001-01-26 CA CA002398794A patent/CA2398794C/en not_active Expired - Fee Related
- 2001-01-26 NZ NZ520342A patent/NZ520342A/en unknown
- 2001-01-26 EP EP01946858A patent/EP1257547B1/en not_active Expired - Lifetime
- 2001-01-26 PL PL356265A patent/PL202473B1/pl not_active IP Right Cessation
- 2001-01-26 CN CNB018042341A patent/CN1178935C/zh not_active Expired - Fee Related
- 2001-01-26 WO PCT/EP2001/000861 patent/WO2001055132A1/en active IP Right Grant
- 2001-01-26 HU HU0203836A patent/HUP0203836A3/hu unknown
- 2001-01-26 BR BR0107888-7A patent/BR0107888A/pt not_active Application Discontinuation
- 2001-01-26 JP JP2001560991A patent/JP2003523353A/ja active Pending
- 2001-01-26 KR KR1020027009705A patent/KR20020069375A/ko not_active Application Discontinuation
- 2001-01-26 DE DE60132558T patent/DE60132558T2/de not_active Expired - Fee Related
- 2001-01-26 CZ CZ20022581A patent/CZ20022581A3/cs unknown
- 2001-01-26 PT PT01946858T patent/PT1257547E/pt unknown
- 2001-01-26 CN CNB2004100839164A patent/CN1305847C/zh not_active Expired - Fee Related
- 2001-01-26 RU RU2002121646/04A patent/RU2002121646A/ru not_active Application Discontinuation
- 2001-01-26 SK SK1080-2002A patent/SK10802002A3/sk unknown
- 2001-01-26 AU AU28501/01A patent/AU768844B2/en not_active Ceased
- 2001-01-26 IL IL15055001A patent/IL150550A0/xx unknown
- 2001-01-29 CO CO01006310A patent/CO5261521A1/es not_active Application Discontinuation
2002
- 2002-07-22 NO NO20023485A patent/NO20023485L/no not_active Application Discontinuation
- 2002-07-26 ZA ZA200205991A patent/ZA200205991B/en unknown

Also Published As

Publication number	Publication date
DE60132558T2 (de)	2009-02-19
CA2398794C (en)	2009-12-08
NZ520342A (en)	2004-08-27
CN1178935C (zh)	2004-12-08
HUP0203836A3 (en)	2005-03-29
EP1257547B1 (en)	2008-01-23
DE60132558D1 (de)	2008-03-13
GB0002100D0 (en)	2000-03-22
AU2850101A (en)	2001-08-07
CN1305847C (zh)	2007-03-21
US7012085B2 (en)	2006-03-14
AU768844B2 (en)	2004-01-08
PT1257547E (pt)	2008-04-23
CN1636977A (zh)	2005-07-13
CZ20022581A3 (cs)	2002-10-16
IL150550A0 (en)	2003-02-12
HUP0203836A2 (hu)	2003-03-28
KR20020069375A (ko)	2002-08-31
WO2001055132A1 (en)	2001-08-02
PL356265A1 (en)	2004-06-28
RU2002121646A (ru)	2004-01-10
CO5261521A1 (es)	2003-03-31
CA2398794A1 (en)	2001-08-02
JP2003523353A (ja)	2003-08-05
BR0107888A (pt)	2002-11-05
AR029463A1 (es)	2003-07-02
NO20023485L (no)	2002-09-03
MY128639A (en)	2007-02-28
US20030008874A1 (en)	2003-01-09
PE20011068A1 (es)	2001-11-15
ATE384715T1 (de)	2008-02-15
PL202473B1 (pl)	2009-06-30
SK10802002A3 (sk)	2003-01-09
EP1257547A1 (en)	2002-11-20
ZA200205991B (en)	2003-10-07
MXPA02007318A (es)	2002-12-13
CN1396920A (zh)	2003-02-12
ES2296763T3 (es)	2008-05-01

Publication	Publication Date	Title
NO20023485D0 (no)	2002-07-22	1,3-disubstituerte pyrrolidiner som alfa-2- adrenoceptorantagonister
NO20043022L (no)	2004-07-15	5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
DE60131971D1 (de)	2008-01-31	1,3,8-TRIAZA-SPIROi4,5 DECAN-4-ONDERIVATIVE ALS NEUROKININREZEPTORANTAGONISTEN
NO20041567L (no)	2004-05-11	1,8-nafthyridinderivater som antidiabetiske midler
DK1463716T3 (da)	2008-06-16	Pyrrolidin- og piperidinderivater som NK1-antagonister
ATE318259T1 (de)	2006-03-15	Selektive neurokinin-antagonisten
DK1309317T3 (da)	2006-06-19	Farmaceutiske præparater, der omfatter amlodipinmaleat
DK1379522T3 (da)	2005-05-30	Dihydro-benzo(b)(1,4)diazeping-2-on-derivater som MGLUR2-antagonister I
NO20032142D0 (no)	2003-05-13	Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
NO20004668D0 (no)	2000-09-19	1-(3-heteroarylpropyl- eller -prop-2-enyl)-4- benzylpiperidiner anvendt som NMDA-reseptorantagonister
DK1339685T3 (da)	2007-03-12	Biphenylcarboxamider, der er egnede som lipidsænkende midler
DK0871623T3 (da)	2003-03-31	3-Azetinidylalkylpiperidiner eller -pyrrolidiner som tachykininantagonister
DK1165547T3 (da)	2003-12-22	Substituerede benzoylpyrazoler som herbicider
DE50107988D1 (de)	2005-12-15	Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
NO20021251D0 (no)	2002-03-13	Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
DK1330458T3 (da)	2009-09-21	N-(1,2,4-triazoloazinyl)thiophensulfonamidforbindelser som herbicider
DE60025958D1 (de)	2006-04-20	14,15-beta-methylen substituierte androgene
NO20030868D0 (no)	2003-02-25	N-(3,5-diklor-2-metoksyfenyl)-4-metoksy-3-piperazin-1-yl- benzensulfonamid
NO20042980L (no)	2004-07-14	3,4-dihydro-1H-isokinolin-2-yl-derivater
DE50105246D1 (de)	2005-03-10	Winkel- bzw. schrägbohr-einrichtung
DK1261588T3 (da)	2005-02-14	Imidazolforbindelser som alfa2-adrenoceptorantagonister
DK0882044T3 (da)	2002-09-02	1,4-dihydropyridinforbindelser som bradykinin-antagonister
IS7131A (is)	2004-01-29	Nýjar 2,4-díamínóþíasól afleiður
ATE470655T1 (de)	2010-06-15	Substituierte 1,5-diaminopentan-3-ol-verbindungen
DK1380585T3 (da)	2005-03-07	Pyrazolopyridinon som mellemprodukt

Legal Events

Date	Code	Title	Description
2006-09-25	FC2A	Withdrawal, rejection or dismissal of laid open patent application